The Toronto Cannabis and Cannabinoid Research Consortium brings together researchers and trainees who are actively engaged in research on cannabis and cannabinoids at the University of Toronto and Toronto Academic Health Sciences Network
TC3 is a tri-campus, multi-institution, interdisciplinary Institutional Strategic Initiative at the University of Toronto
​
Situated at the heart of Canada’s medical research and innovation ecosystem, TC3 has the unique depth and breadth of expertise and the capacity to address almost every crucial and pressing research question related to cannabis and cannabinoids and to translate research findings into real world solutions for society
TC3 is pioneering transformative cannabis and cannabinoid research and training approaches at the convergence of disciplines
The TC3 is led by an interdisciplinary team of researchers from
3 University of Toronto campuses, 6 faculties, 11 departments and 3 hospital and research institutes
MEMBER SPOTLIGHT
My work focuses on pharmacogenomics and pharmacokinetics of substance use disorders. In the cannabis space, for example, this has involved collaborations with scientists testing different cannabis formulations, using LC/MS to examine the plasma/urinary concentrations of THC, CBD and their metabolites, as well as the products (e.g. vapes) themselves.
​
We have also interrogated genetic variants in the endocannabinoid system, for example the influence of FAAH genotypes in different CURB imaging studies and on risk for cannabis use disorder (CUD).
Dr. Rachel Tyndale
University of Toronto
and
Centre for Addiction
and Mental Health
TRAINEE SPOTLIGHT
Yalin studies neuroinflammatory mechanisms mediated by glial cells in non-human primate, rat, and cell culture models to understand how adolescent cannabis exposure might lead to adverse psychiatric outcomes and identify potential therapeutic targets.
Yalin Sun
Lab of Dr. Susan R. George
University of Toronto
ALUMNI SPOTLIGHT
Alexandra Santos is currently working at BlueRock Therapeutics as a Senior Research Associate on the Analytical and Quality Control team. The company focuses on developing stem cell therapy products, and the primary product she supports is a treatment for Parkinson’s Disease, which is presently in clinical trials.
​
In her role, she develops various assays and characterizes the drug product to ensure it meets the stringent quality standards required for continued advancement in the clinical pipeline.
Alexandra Santos
BlueRock Therapeutics
FUNDERS & PARTNERS
